Michael Montemurro1, Sebastian Bauer. 1. Comprehensive Cancer Center, University Hospital Lausanne (CHUV), Lausanne, Switzerland. michael.montemurro@chuv.ch
Abstract
PURPOSE OF REVIEW: Tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, have changed the outcome of patients with gastrointestinal stromal tumor (GIST) and prolonged survival by many-fold. Unfortunately, treatment failure and tumor progression seem inevitable over time and constitute an unresolved clinical challenge. This article reviews current efforts to overcome drug resistance and progression. RECENT FINDINGS: The major mechanism of resistance toward imatinib and sunitinib is the development of secondary resistance mutations in the kinase domain of KIT. Recent efforts aim at inhibitors with increased activity against resistance mutations or a broader spectrum of activity. Other strategies include indirect KIT inhibition by modulating KIT chaperone proteins or inhibition of KIT-dependent and independent signaling pathways. SUMMARY: The rapid improvement of our understanding of GIST biology as well as resistance mechanisms towards imatinib and sunitinib will greatly facilitate the development of novel treatment strategies. This article summarizes the results of recently reported third and fourth-line clinical trials in patients with resistant GIST and reviews data of important proof-of-concept studies.
PURPOSE OF REVIEW: Tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, have changed the outcome of patients with gastrointestinal stromal tumor (GIST) and prolonged survival by many-fold. Unfortunately, treatment failure and tumor progression seem inevitable over time and constitute an unresolved clinical challenge. This article reviews current efforts to overcome drug resistance and progression. RECENT FINDINGS: The major mechanism of resistance toward imatinib and sunitinib is the development of secondary resistance mutations in the kinase domain of KIT. Recent efforts aim at inhibitors with increased activity against resistance mutations or a broader spectrum of activity. Other strategies include indirect KIT inhibition by modulating KIT chaperone proteins or inhibition of KIT-dependent and independent signaling pathways. SUMMARY: The rapid improvement of our understanding of GIST biology as well as resistance mechanisms towards imatinib and sunitinib will greatly facilitate the development of novel treatment strategies. This article summarizes the results of recently reported third and fourth-line clinical trials in patients with resistant GIST and reviews data of important proof-of-concept studies.
Authors: Hemant Kulkarni; Harald H H Göring; Joanne E Curran; Vincent Diego; Thomas D Dyer; Shelley Cole; Ken R Walder; Greg R Collier; John Blangero; Melanie A Carless Journal: Cancer Chemother Pharmacol Date: 2013-02-19 Impact factor: 3.333
Authors: A Brett Hauber; Juan Marcos Gonzalez; John Coombs; Andres Sirulnik; David Palacios; Norman Scherzer Journal: Patient Prefer Adherence Date: 2011-06-24 Impact factor: 2.711
Authors: Barira Islam; Petr Stadlbauer; Miroslav Krepl; Jaroslav Koca; Stephen Neidle; Shozeb Haider; Jiri Sponer Journal: Nucleic Acids Res Date: 2015-08-05 Impact factor: 16.971